A scathing report by Citron Research, which has called U.S. based Valeant Pharmaceuticals the “pharmaceutical Enron”, has alleged that Valeant has been propping it’s topline using less than ethical means.
It is alleged that the company uses mail order pharmacies, which are owned by it to push high priced drugs to it’s patients, and prevents them from switching over to cheaper alternatives.
As a result, Valeant stocks plumetted by 19 percent, and trading had to be halted in the stock.
